p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein

International Journal of Gynecological Pathology

Volumn 16, Issue 4, 1997, Pages 361-368

  Backe, Jaël ^a   Gassel, Andrea M ^a   Hauber, Kristina ^a   Krebs, Stefan ^a   Bartek, Jan ^b   Caffier, Hans ^a   Kreipe, Hans Heinrich ^a   Müller Hermelink, Hans Konrad ^a   Dietl, Johannes ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Endometrial carcinoma; Immunohistochemistry; p21; p53; Proliferative activity; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; ENDOMETRIUM CANCER; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; UTERUS CANCER;

EID: 0030865134     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199710000-00011     Document Type: Article

References (52)

1. Shaw PH. The role of p53 in cell cycle regulation. Path Res Pract 1996;192:669-75.
2. Poremba C, Bankfalvi A, Dockhom-Dworniczak B. Das Tumorsuppressorgen p53. Pathologe 1996;17:181-8.
3. Yin XM, Oltval ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994;369:321-3
4. Kastan MB, Onyekwere O, Sidransky B, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
5. Hall PA, Lane DP. P53 in tumor pathology: Can we trust immunohistochemistry? J Pathol 1994;172,1-4.
6. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429-31.
7. Fearon ER. Genetic alterations underlying colorectal tumorigenesis. Cancer Surv 1992;12:119-36.
8. Hurlimann J. Prognostic value of p53 protein expression in breast carcinomas. Path Res Pract 1993;189:996-1003.
9. Kohlberger P, Gitsch G, Loesch A, et al. P53 protein overexpression in early stage endometrial cancer. Gynecol Oncol 1996;62: 213-47.
10. Poremba C, Yandell DW, Huang Q, et al. Frequency and spectrum of p53 mutations in gastric cancer - a molecular genetic and immunohistochemical study. Virchows Arch 1995;426:447-55.
11. Poremba C, Yandell DW, Metze D, Kamabrou D, Böcker W, Dockhorn-Dworniczak B. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutation is associated with mdm-2 overexpression. Oncol Res 1995;7:331-9.
12. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 1992;84:845-55.
13. Sun XF, Carstensen JF, Zhang H, Stal O, Wingren S, Hatschek T. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 1992;340:1369-73.
14. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. P53 expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50:859-62.
15. Kohlberger P, Kainz C, Breitenecker G, et al. Prognostic value of immunohistochemically detected p53 expression in vulvar carcinoma. Cancer 1995;76:1786-9.
16. Kohlberger P, Breitenecker G, Gitsch G, et al. Die p53-Überexpression als prognostischer Faktor beim Vulvakarzinom. Gynäkol Geburtshilfliche Rundsch 1996;36:37-45.
17. Hamel N. W, Sebo T. J, Wilson T. O, et al. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gyencol Oncol 1996;62:192-8.
18. Lukes A. S, Kohler M. F, Pieper C. F, et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 1994;73:2380-5.
19. Berchuck A. Biomarkers in the endometrium. J Cell Biochem Suppl 1995;23:174-8.
20. Elledge SJ, Harper JW. Cdk inhibitors: on a threshold of check-points and development. Curr Opin Cell Biol 1994;6:847-52.
21. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
22. El-Deiry WS, Tokino T, Velculescu V. E, et al. WAF-1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
23. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. P21 is a universal inhibitor of cyclin kinases. Nature 1993;366: 701-4.
24. Noda A, Ning Y, Venable S. F, Pereira-Smith O. M, Smith J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994;211:90-8.
25. FIGO stages: 1988 revision. Gynecol Oncol 1989;35:125-127.
26. World Health Organization. Histologic typing of female genital tract tumours. International Histological Classification of Tumours 1994;13.
27. Remmele W, Stegner HE. Vorschlag zur einheitlichen Definition eines immunreaktiven Score (IRS) für den immunohistochemischen Östrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe. Pathologie 1987;8:138-40.
28. Segreti EM, Novotny DB, Soper J. T, Mutch D. G, Creasman W. T, McCarty K. S. Endometrial cancer: histologic correlates of immunohistochemical localization of progesterone and estrogen receptor. Obstet Gynecol 1989;73:780-4.
29. Backe J, Gassel AM, Müller T, Schön S, Kaesemann H. Die Proliferationsrate als Prognosekriterium beim Endometriumkarzinom - eine immunhistochemische Analyse mit dem monoklonalen Antikörper Ki-S1. Zentralbl Gynakol 1997;119:334-42.
30. Kreipe HH, Alm P, Olsson H, Hauberg M, Fischer L, Parwaresch MR. Prognostic significance of a formalin resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Am J Pathol 1993;142:651-7.
31. Grund C. MEDAS, Statistikprogramm für Medizin und Biowissenschaften. Würzburg, Germany: MEDAS, 1995:I1-VI3.
32. Rose PG. Endometrial carcinoma. N Engl J Med 1996;335:640-9.
33. Zheng W, Cao P, Zheng M, Kramer EE, Godwin TA. P53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 1996;61:167-74.
34. Li SF, Shiozawa T, Nakayama K, Nikaido T, Fujii S. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma. Cancer 1996;77:321-9.
35. Berchuck A, Boyd J. Molecular basis of endometrial cancer. Cancer 1995;76:2034-40.
36. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994;170:246-52.
37. Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52: 1622-7.
38. Kohler MF, Nishii H, Humphrey PA, et al. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. Am J Obstet Gynecol 1993;169:690-4.
39. Kohler MF, Carney P, Dodge R, Soper JT, Clarke-Pearson DL. Marks J. R, Berchuck A. P53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol 1996;175: 1246-52.
40. Inoue M, Okayama A, Fujita M, Enomoto T, Sakata M, Tanizawa O, Ueshima H. Clinicopathological characteristics of p53 overexpression in endometrial cancers. Int J Cancer 1994;58:14-9.
41. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG. P53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992;98: 81-7.
42. Lambkin HA, Mothersill CM, Kelehan P. Variations in immunohistochemical detection of p53 protein overexpression J Pathol 1994;172:13-8.
43. Riethdorf L, Begemann C, Riethdorf S, Milde-Langosch K, Loning T. Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature-gradient electrophoresis. Virchows Arch 1996;428:47-51.
44. Ito K, Watanabe K, Nasim S, et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 1994;54:4667-70.
45. Hachisuga T, Fukuda K, Uchiyama M, Matsuo N, Iwasaka T, Sugimori H. Immunohistochemical study of p53 expression in endometrial carcinomas: correlation with markers of proliferating cells and clinicipathologic features. Int J Cancer 1993;3:363-8.
46. Yamauchi N, Sakamoto A, Uozaki H, Iihara K, Machinami R. Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int J Gynecol Pathol 1996;15:202-8.
47. Gerken, SC. Albertsen H, Eisner T, et al. A strategy for constructing high-resolution genetic maps of the human genome: a genetic map of chromosome 17p, ordered with meiotic breakpoint-mapping panels. Am J Hum Genet 1995;56:484-99.
48. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway Cancer Res 1994;54:3391-5.
49. Nikaido T, Li SF, Shiozawa T, Fujii S. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas. Cancer 1996;78:1248-53.
50. Di Giuseppe JA, Redston MS, Yeo CJ, Kem SE, Hruban RH. P53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995;147:884-8.
51. Barboule N, Mazars P, Baldin V, Vidai S, Jozan S, Martel P, Valletta A. Expression of p21 (WAF1/CIP1) is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int J Cancer 1995;63:611-5.
52. Elbendary A, Berchuck A, Davis P, Havrilesky, L, Bast R. C, Iglehart JD, Marks JR. Transforming growth factor b1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth and Diff 1994;5:1301-7.